Glaukos Sets Stage for Q2 Results Amid Strong Growth & Eye Care Innovation

ALISO VIEJO, CA – July 08, 2026 – Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology and pharmaceuticals, has scheduled the release of its second quarter 2026 financial results for after market close on Wednesday, July 29, 2026. The announcement will be followed by a conference call where investors, analysts, and the public can hear directly from management about the company's recent performance and strategic outlook. The upcoming report is highly anticipated, as it follows a period of record-setting growth and significant commercial advancements for its portfolio of transformative eye care therapies.

As a pioneer in Micro-Invasive Glaucoma Surgery (MIGS) and a developer of novel treatments for corneal and retinal diseases, Glaukos has established itself as a key innovator in ophthalmology. The Q2 results will provide the first comprehensive look at the company's performance following major reimbursement milestones and continued market penetration of its flagship products, offering critical insights into its growth trajectory for the remainder of the year and beyond.

Riding a Wave of Strong Financial Momentum

Expectations for the second quarter are set against the backdrop of an exceptionally strong start to 2026. In the first quarter, Glaukos delivered record net sales of $150.6 million, a remarkable 41% increase year-over-year. This performance handily surpassed analyst projections of $137.04 million, signaling robust demand for its products and effective commercial execution.

The driving force behind this surge was the company's Glaucoma franchise, which posted net sales of $129.3 million, up 47% from the prior year. The U.S. market was particularly strong, with glaucoma sales growing an impressive 58%. This powerful top-line growth prompted the company to raise its full-year 2026 net sales guidance to a range of $620 million to $635 million, an upward revision from its initial forecast.

While continuing to invest heavily in growth initiatives, the company also demonstrated improving operational leverage. Its non-GAAP net loss of ($0.18) per share was significantly better than the analyst consensus of ($0.28), indicating disciplined management. Glaukos maintains a solid financial foundation, ending the first quarter with approximately $280.5 million in cash and cash equivalents and no debt, providing ample flexibility to fund its ongoing R&D and commercial activities. For the upcoming Q2 release, analyst consensus points to expected revenues of around $151 million, with investors keen to see if the company can sustain its powerful momentum.

Innovation in Sight: Commercial Success of Key Therapies

The financial success story is intrinsically linked to the clinical impact and commercial adoption of Glaukos's innovative therapies. The company's first-of-its-kind, long-duration glaucoma therapy, iDose® TR, has been a standout performer since its launch. In the first quarter alone, the intracameral procedural pharmaceutical generated approximately $54 million in sales, rapidly becoming a cornerstone of the Glaucoma franchise.

iDose® TR is designed to deliver a therapeutic dose of medication 24/7 from within the eye, addressing the widespread challenge of patient non-adherence to daily eye drop regimens. The strong clinical outcomes and positive physician feedback have fueled its rapid adoption. The upcoming earnings call will be an opportunity for management to provide an update on its market penetration and the ongoing efforts to secure favorable reimbursement coverage, which has seen positive developments with proposed Local Coverage Determinations from Medicare Administrative Contractors.

"The ability to provide continuous drug therapy inside the eye is a paradigm shift for how we manage chronic diseases like glaucoma," noted one ophthalmic surgeon. "It offers a level of consistency that is simply not possible with topical drops, potentially leading to better long-term outcomes for patients."

Expanding Vision Beyond Glaucoma

While founded on its success in glaucoma, Glaukos has strategically diversified its portfolio to address other significant unmet needs in eye care, particularly in corneal health. The company's Corneal Health franchise, which grew 15% year-over-year in Q1, is at a pivotal moment with the commercial launch of Epioxa, its next-generation therapy for the progressive corneal disorder keratoconus.

Epioxa, which recorded $17.7 million in early sales in the first quarter, is set to benefit from a major commercial catalyst. Effective July 1, 2026, the therapy was assigned a permanent J-code (J2789) by the Centers for Medicare & Medicaid Services (CMS). This dedicated reimbursement code is a critical milestone that streamlines billing and payment processes for providers, which is expected to significantly expand payer coverage and accelerate patient access across the United States. With market access pathways already established for over 100 million commercially covered lives, the J-code is poised to unlock the therapy's full potential.

While the company has guided for some near-term sales volatility as the market transitions from its predecessor product, Photrexa, to Epioxa, the long-term outlook for the franchise is bright. The upcoming financial report will offer the first glimpse into the early impact of this new reimbursement landscape. The company also continues to see success internationally, with its iStent infinite MIGS device gaining traction in Europe following its commercial launch in late 2025, though it continues to navigate a competitive international landscape.

A Robust Pipeline for Future Eye Care Frontiers

Glaukos's commitment to advancing the standard of care extends deep into its research and development pipeline. The company is actively developing a suite of novel, dropless platform technologies aimed at treating a range of chronic eye diseases. A recent milestone underscores this forward-looking vision: on June 25, 2026, Glaukos announced the completion of patient enrollment in its Phase 2 study of GLK-321, a potential treatment for Demodex blepharitis, a common and often irritating eyelid condition.

This progress demonstrates the company's strategy to leverage its expertise in drug delivery and ophthalmic pharmaceuticals to expand into new therapeutic areas with significant patient populations. This robust R&D engine is fundamental to the company's long-term growth strategy, promising future innovations that could further diversify its revenue streams and solidify its leadership position in ophthalmology.

As Glaukos prepares to share its Q2 2026 results on July 29, investors and the broader healthcare community will be listening for updates not only on its stellar commercial performance but also on the continued progress of a pipeline that holds the promise of shaping the future of eye care for years to come.